
N Paul Ohori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3966074/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3390-3397.	3.6	712
2	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 nextâ€generation sequencing assay. Cancer, 2014, 120, 3627-3634.	4.1	445
3	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid, 2015, 25, 1217-1223.	4.5	344
4	Contribution of molecular testing to thyroid fineâ€needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance― Cancer Cytopathology, 2010, 118, 17-23.	2.4	229
5	Variability in the Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: Sources and Recommendations. Acta Cytologica, 2011, 55, 492-498.	1.3	136
6	<i>RAS</i> Mutations in Thyroid FNA Specimens Are Highly Predictive of Predominantly Low-Risk Follicular-Pattern Cancers. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E914-E922.	3.6	128
7	Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer. Annals of Surgery, 2015, 262, 519-525.	4.2	100
8	Occurrence of Human Papillomavirus DNA in Primary Lung Neoplasms. Cancer, 1992, 69, 693-697.	4.1	94
9	<i>PAX8/PPARÎ³</i> Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma. Thyroid, 2014, 24, 1369-1374.	4.5	83
10	Adequacy of Core Needle Biopsy Specimens and Fine-Needle Aspirates for Molecular Testing of Lung Adenocarcinomas. American Journal of Clinical Pathology, 2015, 143, 193-200.	0.7	79
11	A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma. Endocrine Pathology, 2009, 20, 122-126.	9.0	74
12	<i>BRAF</i> mutation detection in indeterminate thyroid cytology specimens. Cancer Cytopathology, 2013, 121, 197-205.	2.4	71
13	Thyroid nodules with <i>KRAS</i> mutations are different from nodules with <i>NRAS</i> and <i>HRAS</i> mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathology, 2014, 122, 873-882.	2.4	63
14	Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery, 2017, 161, 168-175.	1.9	56
15	Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathology, 2019, 127, 161-168.	2.4	50
16	Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. Surgery, 2018, 163, 81-87.	1.9	46
17	The influence of the noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features (NIFTP) resection diagnosis on the falseâ€positive thyroid cytology rate relates to quality assurance thresholds and the application of NIFTP criteria. Cancer Cytopathology, 2017, 125, 692-700.	2.4	39
18	Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery, 2013, 154, 730-738.	1.9	34

N PAUL OHORI

#	Article	IF	CITATIONS
19	Cancer risk and clinicopathological characteristics of thyroid nodules harboring thyroidâ€stimulating hormone receptor gene mutations. Diagnostic Cytopathology, 2018, 46, 369-377.	1.0	30
20	Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer Cytopathology, 2021, 129, 33-42.	2.4	30
21	Cytopathology of high-grade papillary thyroid carcinomas: Tall-cell variant, diffuse sclerosing variant, and poorly differentiated papillary carcinoma. , 1999, 20, 19-23.		29
22	Endoscopic ultrasound–guided <scp>FNA</scp> and <scp>P</scp> ro <scp>C</scp> ore biopsy in sampling pancreatic and intraâ€abdominal masses. Cancer Cytopathology, 2016, 124, 110-121.	2.4	29
23	The Clinical Utility of Molecular Testing in the Management of Thyroid Follicular Neoplasms (Bethesda IV Nodules). Annals of Surgery, 2020, 272, 621-627.	4.2	23
24	Molecular-derived estimation of risk of malignancy for indeterminate thyroid cytology diagnoses. Journal of the American Society of Cytopathology, 2020, 9, 213-220.	0.5	23
25	Molecular alterations in HÃ1/4rthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	3.1	23
26	<i>GLIS</i> rearrangements in thyroid nodules: A key to preoperative diagnosis of hyalinizing trabecular tumor. Cancer Cytopathology, 2019, 127, 560-566.	2.4	21
27	"Colloidâ€Rich―follicular neoplasm/suspicious for follicular neoplasm thyroid fineâ€needle aspiration specimens: Cytologic, histologic, and molecular basis for considering an alternate view. Cancer Cytopathology, 2013, 121, 718-728.	2.4	20
28	Double Slide Viewing as a Cytology Quality Improvement Initiative. American Journal of Clinical Pathology, 2006, 125, 526-533.	0.7	19
29	Intraoperative Pathologic Examination in the Era of Molecular Testing for Differentiated Thyroid Cancer. Journal of the American College of Surgeons, 2012, 215, 546-554.	0.5	18
30	Correlation of Ultrasound Findings With the Bethesda Cytopathology Classification for Thyroid Nodule Fine-Needle Aspiration: A Primer for Radiologists. American Journal of Roentgenology, 2013, 201, W487-W494.	2.2	14
31	Dramatic response of adult Wilms tumor to paclitaxel and cisplatin. , 2000, 34, 296-298.		11
32	Bronchoscopic and transthoracic cytology and biopsy for pulmonary nonsmall cell carcinomas: Performance characteristics by procedure and tumor type. Diagnostic Cytopathology, 2012, 40, 659-663.	1.0	10
33	Molecular testing and thyroid nodule management in North America. Gland Surgery, 2020, 9, 1628-1638.	1.1	10
34	Cytologic-histologic correlation of nongynecologic cytopathology cases: Separation of determinate from indeterminate cytologic diagnoses for analysis and monitoring of laboratory performance. Diagnostic Cytopathology, 2003, 28, 28-34.	1.0	9
35	Committee I: Indications for pulmonary cytology sampling methods. Diagnostic Cytopathology, 2016, 44, 1010-1023.	1.0	9
36	Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fineâ€needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type. Cancer Cytopathology, 2021, 129, 788-797.	2.4	9

N PAUL OHORI

#	Article	IF	CITATIONS
37	Epithelioid Hemangioendothelioma: a Rare Primary Thyroid Tumor with Confirmation of WWTR1 and CAMTA1 Rearrangements. Endocrine Pathology, 2016, 27, 147-152.	9.0	8
38	Comparison of urinary cytology and fluorescence in situ hybridization in the detection of urothelial neoplasia: An analysis of discordant results. Diagnostic Cytopathology, 2019, 47, 282-288.	1.0	8
39	Discrepancy analysis, communication, and feedback for cytotechnologist quality improvement of nongynecologic cytopathology. Diagnostic Cytopathology, 2006, 34, 265-269.	1.0	5
40	Percutaneous computed tomography–guided biopsy performed by thoracic surgeons in 955 patients: A paradigm shift in image-guided thoracic procedures. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1239-1245.	0.8	5
41	Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict Patient Outcome. Clinical Gastroenterology and Hepatology, 2020, , .	4.4	5
42	A decade into thyroid molecular testing: where do we stand?. Journal of the American Society of Cytopathology, 2022, 11, 59-61.	0.5	5
43	Critical diagnoses in cytopathology: Experience at a large medical center. Cancer Cytopathology, 2017, 125, 726-730.	2.4	4
44	Comparison of the collection approaches of 2 large thyroid fine-needle aspiration practices reveals differing advantages for cytology and molecular testing adequacy rates. Journal of the American Society of Cytopathology, 2019, 8, 243-249.	0.5	4
45	Thyroid Cytology: Challenges in the Pursuit of Low-Grade Malignancies. Radiologic Clinics of North America, 2011, 49, 435-451.	1.8	3
46	Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features. Cancer Cytopathology, 2017, 125, 292-293.	2.4	2
47	Incidental Diagnosis of Parathyroid Lesions by Preoperative Use of Nextâ€Generation Molecular Testing. World Journal of Surgery, 2018, 42, 2840-2845.	1.6	2
48	Comparison of quantitative internal and external measures of performance for trainees in cytopathology fellowships. Journal of the American Society of Cytopathology, 2021, 10, 495-503.	0.5	2
49	Accuracy of definitive rapid onsite evaluation cytopathology diagnoses: Assessment of potentially critical diagnoses as a quality assurance measure. Journal of the American Society of Cytopathology, 2022, 11, 133-141.	0.5	2
50	Selective screening for nongynecologic cytology specimens: Modifying the screening process for improved efficiency and practice. Diagnostic Cytopathology, 2011, 39, 717-722.	1.0	1
51	Ancillary Studies in Thyroid Cytopathology. Surgical Pathology Clinics, 2014, 7, 47-60.	1.7	1
52	Significance of what is not sampled: Characteristics of thyroid nonmicrocarcinomas (>1.0 cm) that were not targeted. Cancer Cytopathology, 2015, 123, 678-683.	2.4	1
53	Cytopathology of highâ€grade papillary thyroid carcinomas: Tallâ€cell variant, diffuse sclerosing variant, and poorly differentiated papillary carcinoma. Diagnostic Cytopathology, 1999, 20, 19-23.	1.0	1

54 Thyroid Fine-Needle Aspiration Cytology Molecular Testing in the USA., 2019, , 451-463.

0

#	Article	IF	CITATIONS
55	A diagnostically difficult case of a cellular pleural fluid: Morphology, immunohistochemistry, and fluorescence in situ hybridization study. CytoJournal, 2017, 14, 18.	1.7	Ο